blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3661560

EP3661560 - COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  19.09.2024
Database last updated on 19.10.2024
FormerExamination is in progress
Status updated on  11.05.2021
FormerRequest for examination was made
Status updated on  08.05.2020
FormerThe international publication has been made
Status updated on  09.02.2019
Formerunknown
Status updated on  06.08.2018
Most recent event   Tooltip19.09.2024New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
For all designated states
Bayer Aktiengesellschaft
Kaiser-Wilhelm-Allee 1
51373 Leverkusen / DE
[2020/24]
Inventor(s)01 / WENGNER, Antje, Margret
Binzstr. 60
13189 Berlin / DE
 [2020/24]
Representative(s)BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 50
40789 Monheim am Rhein / DE
[N/P]
Former [2020/24]BIP Patents
c/o Bayer Intellectual Property GmbH
Alfred-Nobel-Straße 10
40789 Monheim am Rhein / DE
Application number, filing date18745636.331.07.2018
[2020/24]
WO2018EP70729
Priority number, dateEP2017018495004.08.2017         Original published format: EP 17184950
[2020/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019025440
Date:07.02.2019
Language:EN
[2019/06]
Type: A1 Application with search report 
No.:EP3661560
Date:10.06.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 07.02.2019 takes the place of the publication of the European patent application.
[2020/24]
Search report(s)International search report - published on:EP07.02.2019
ClassificationIPC:A61K45/06, C07D471/04
[2020/24]
CPC:
A61K45/06 (EP); A61K39/3955 (US); A61K31/497 (US);
A61K31/519 (US); A61K31/5377 (US); A61P35/00 (US);
C07D471/04 (EP); A61K2039/505 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/24]
TitleGerman:KOMBINATION VON ATR-KINASEHEMMERN UND PD-1/PD-L1-HEMMERN[2020/24]
English:COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS[2020/24]
French:COMBINAISON D'INHIBITEURS DE KINASE ATR ET D'INHIBITEURS DE PD-1/PD-L1[2020/24]
Entry into regional phase04.03.2020National basic fee paid 
04.03.2020Designation fee(s) paid 
04.03.2020Examination fee paid 
Examination procedure04.03.2020Examination requested  [2020/24]
04.03.2020Date on which the examining division has become responsible
08.09.2020Amendment by applicant (claims and/or description)
11.05.2021Despatch of a communication from the examining division (Time limit: M08)
21.01.2022Reply to a communication from the examining division
24.05.2022Despatch of a communication from the examining division (Time limit: M06)
25.11.2022Reply to a communication from the examining division
05.07.2023Despatch of a communication from the examining division (Time limit: M06)
03.01.2024Reply to a communication from the examining division
20.09.2024Communication of intention to grant the patent
Fees paidRenewal fee
14.07.2020Renewal fee patent year 03
15.07.2021Renewal fee patent year 04
28.06.2022Renewal fee patent year 05
29.06.2023Renewal fee patent year 06
26.06.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XDI]WO2016020320  (BAYER PHARMA AG [DE]);
 [X]WO2017106556  (GILEAD SCIENCES INC [US]);
 [X]WO2017121684  (BAYER PHARMA AG [DE])
by applicantUS5011472
 US5023252
 WO2010054398
 WO2010071837
 WO2010073034
 WO2011143399
 WO2011143419
 WO2011143422
 WO2011143423
 WO2011143425
 WO2011143426
 WO2011154737
 WO2011163527
 WO2012138938
 WO2012178123
 WO2012178124
 WO2012178125
 WO2013049719
 WO2013049720
 WO2013049722
 WO2013049859
 WO2013071085
 WO2013071088
 WO2013071090
 WO2013071093
 WO2013071094
 WO2013152298
 WO2014062604
 WO2014089379
 WO2014143240
 WO2014143241
 WO2014143242
 WO2015085132
 WO2015187451
 WO2016020320
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.